ATE483979T1 - Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa - Google Patents

Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa

Info

Publication number
ATE483979T1
ATE483979T1 AT05770407T AT05770407T ATE483979T1 AT E483979 T1 ATE483979 T1 AT E483979T1 AT 05770407 T AT05770407 T AT 05770407T AT 05770407 T AT05770407 T AT 05770407T AT E483979 T1 ATE483979 T1 AT E483979T1
Authority
AT
Austria
Prior art keywords
cancer
anln
rhoa
small cell
cell lung
Prior art date
Application number
AT05770407T
Other languages
German (de)
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE483979T1 publication Critical patent/ATE483979T1/de

Links

Classifications

    • G01N33/5752—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05770407T 2004-08-10 2005-08-09 Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa ATE483979T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60056104P 2004-08-10 2004-08-10
PCT/JP2005/014887 WO2006016697A1 (en) 2004-08-10 2005-08-09 Non-small cell lung cancer-related gene, anln, and its interactions with rhoa

Publications (1)

Publication Number Publication Date
ATE483979T1 true ATE483979T1 (de) 2010-10-15

Family

ID=35355888

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770407T ATE483979T1 (de) 2004-08-10 2005-08-09 Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa

Country Status (6)

Country Link
US (1) US20090297500A1 (cg-RX-API-DMAC7.html)
EP (1) EP1787122B1 (cg-RX-API-DMAC7.html)
JP (1) JP4874234B2 (cg-RX-API-DMAC7.html)
AT (1) ATE483979T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005024021D1 (cg-RX-API-DMAC7.html)
WO (1) WO2006016697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131476B2 (en) 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
US8060348B2 (en) 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
AU2007322206A1 (en) * 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
EP2142648A4 (en) * 2007-03-30 2011-09-14 Oncotherapy Science Inc SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX
EP2161577A1 (en) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
JP6127972B2 (ja) 2011-09-09 2017-05-17 コニカミノルタ株式会社 組織染色方法
ES2674318T3 (es) * 2011-10-24 2018-06-28 Somalogic, Inc. Biomarcadores de cáncer de pulmón y usos de los mismos
JP5806168B2 (ja) * 2012-06-19 2015-11-10 国立大学法人 岡山大学 抗浸潤薬の新規スクリーニング法
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10870854B2 (en) 2016-06-09 2020-12-22 The Board Of Regents Of The University Of Texas System Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA2522299A1 (en) * 2003-04-15 2004-10-28 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods

Also Published As

Publication number Publication date
JP2008510126A (ja) 2008-04-03
EP1787122B1 (en) 2010-10-06
EP1787122A1 (en) 2007-05-23
WO2006016697A1 (en) 2006-02-16
JP4874234B2 (ja) 2012-02-15
US20090297500A1 (en) 2009-12-03
DE602005024021D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
ATE483979T1 (de) Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa
FR21C1064I2 (fr) Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
IL258880A (en) Diarylhydantoin compounds
WO2009049214A3 (en) Inhibition and treatment of prostate cancer metastasis
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
WO2014144657A3 (en) Compositions and methods for cancer prognosis
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
CY1118612T1 (el) Μεθοδοι και χημικες συνθεσεις για την θεραπευτικη αντιμετωπιση των εμμενουσων λοιμωξεων και του καρκινου μεσω αναστολης της οδου προγραμματισμενου κυτταρικου θανατου 1 (pd-1)
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
WO2020239895A3 (en) Detection of colorectal cancer
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
WO2010042933A3 (en) Inhibition and treatment of prostate cancer metastasis
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
BRPI0403169A (pt) Prognósticos de câncer colorretal
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
DE602006005084D1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
TW200716132A (en) Novel chemical compounds
WO2006086772A3 (en) DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen
WO2023004342A3 (en) Methods for identifying adar1 inhibitors, and compositions and methods of use in treating cancer
TW200716579A (en) Novel chemical compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties